Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals-Reference-Cited by-同舟云学术

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals

Published:2014-05-14 Issue:1 Volume:60 Page:37-45
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Hagan Liesl M.¹,Sulkowski Mark S.²,Schinazi Raymond F.¹

Affiliation:

1. Center for AIDS Research; Emory University School of Medicine and Veterans Affairs Medical Center; Atlanta GA

2. Johns Hopkins University School of Medicine; Baltimore MD

Funder

National Institutes of Health

U.S. Department of Veterans Affairs

Publisher

Wiley

Subject

Hepatology

Reference50 articles.

1. HCV direct-acting antiviral agents: the best interferon-free combinations;Schinazi;Liver Int,2014

2. 2014 http://www.hcvguidelines.org/full-report-view

3. U.S. Food and Drug Administration. OLYSIO 2013 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf

4. U.S. Food and Drug Administration. SOVALDI. 2013 http://www.accessdata.fda.gov/spl/data/b0de1fcd-6d03-4a91-a7df-72a14c8bc7d0/b0de1fcd-6d03-4a91-a7df-72a14c8bc7d0.xml

5. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection;Bini;Am J Gastroenterol,2005

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Direct-Acting Antivirals Remain Cost-Effective Treatments for Chronic Hepatitis C in Australia Despite Changes to the Treated Population and the Availability of Retreatment: The Glecaprevir/Pibrentasvir (Maviret®) Example;Infectious Diseases and Therapy;2024-03

2. Is it time for China to prioritize pan-genotypic regimens for treating patients with hepatitis C?;Cost Effectiveness and Resource Allocation;2024-02-06

3. Scale-up of direct-acting antiviral treatment in prisons is both cost-effective and key to HCV elimination;Open Forum Infectious Diseases;2023-12-18

4. Identifying barriers and facilitators of the inclusion of pregnant individuals in hepatitis C treatment programs in the United States;PLOS ONE;2022-11-18

5. Value of Triage Treatment Strategies to Distribute Hepatitis C Direct-Acting Antiviral Agents in an Integrated Healthcare System: A Cost-Effectiveness Analysis;Value in Health;2022-09